- Home
- IMMP
IMMP
Immutep Limited
as 05-14-2024 4:00pm EST
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
| Founded: | N/A | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 357.8M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 222.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $3.90 | Next Earning Date: | 05-28-2024 |
| Revenue: | $4,576,733 | Revenue Growth: | 47.55% |
| Revenue Growth (this year): | 62.78% | Revenue Growth (next year): | 316.81% |
Share on Social Networks:
Latest Immutep Limited News
IMMP Breaking Stock News: Dive into IMMP Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
GlobeNewswire
16 days ago
Immutep Quarterly Activities Report Q3 FY24
MT Newswires
20 days ago
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
Benzinga
20 days ago
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
GlobeNewswire
21 days ago
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
GlobeNewswire
a month ago
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
GlobeNewswire
a month ago
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Simply Wall St.
2 months ago